贝特类药物在原发性胆汁性胆管炎中的应用及作用机制

武李红; 韩英

doi:10.3969/j.issn.1001-5256.2016.12.038

贝特类药物在原发性胆汁性胆管炎中的应用及作用机制

DOI: 10.3969/j.issn.1001-5256.2016.12.038

武李红,
韩英

第四军医大学西京消化病医院肿瘤生物学国家重点实验室

详细信息

中图分类号: R575.7
计量
- 文章访问数: 2304
- HTML全文浏览量: 39
- PDF下载量: 502
- 被引次数: 0
出版历程
- 出版日期: 2016-12-20

Application and role of fibrates in treatment of primary biliary cholangitis and related mechanisms

Wu LiHong,
Han Ying

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种自身免疫介导的慢性胆汁淤积性肝病。熊去氧胆酸(UDCA)是唯一经美国食品药品监督管理局批准的治疗PBC安全有效的药物。对UDCA应答不佳的患者应如何处理,目前尚无统一的方案。贝特类降脂药是一类人工合成的过氧化物酶体增殖物激活受体的配体,目前研究认为其具有抗胆汁淤积、抗炎及抗纤维化的作用。综述了贝特类药物在PBC治疗中的应用及可能存在的机制。
- 肝硬化,胆汁性 /
- 氯贝酸 /
- 熊脱氧胆酸 /
- 过氧化物酶体增殖物激活受体 /
- 综述
Abstract: Primary biliary cholangitis( PBC) is an autoimmune chronic cholestatic liver disease. Ursodeoxycholic acid( UDCA) is the only safe and effective drug for PBC approved by FDA. To date,there is no unified therapeutic regimen for patients with suboptimal response to UDCA. Fibrates are a class of synthesized ligands of peroxisome proliferator- activated receptors,and recent studies have shown that fibrates may have anticholestatic,anti- inflammatory,and antifibrotic effects. The article reviews the application of fibrates in the treatment of PBC and possible mechanisms.
- liver cirrhosis,biliary /
- clofibric acid /
- ursodeoxycholic acid /
- peroxisome proliferator-activated receptors /
- review

HTML全文

参考文献(35)

[1]BOONSTRA K,BEUERS U,PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol,2012,56(5):1181-1188.

[2]ARNDTZ K,HIRSCHFIELD GM.The pathogenesis of autoimmune liver disease[J].Dig Dis,2016,34(4):327-333.

[3]ZHANG LN,SHI TY,SHI XH,et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study[J].Hepatology,2013,58(1):264-272.

[4]LAMMERT C,JURAN BD,SCHLICHT E,et al.Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients[J].J Gastroenterol,2014,49(10):1414-1420.

[5]RUDIC JS,POROPAT G,KRSTIC MN,et al.Ursodeoxycholic acid for primary biliary cirrhosis[J].Cochrane Database Syst Rev,2012,12:CD000551.

[6]TRIVEDI PJ,LAMMERS WJ,van BUUREN HR,et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut,2016,65(2):321-329.

[7]ANGULO P,JORGENSEN RA,KEACH JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology,2000,31(2):318-323.

[8]LEVY C.Targeting the farnesoid x receptor in patients with cholestatic liver disease[J].Gastroenterol Hepatol(N Y),2016,12(4):263-265.

[9]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.

[10]SHIPMAN KE,STRANGE RC,RAMACHANDRAN S.Use of fibrates in the metabolic syndrome:a review[J].World J Diabetes,2016,7(5):74-88.

[11]Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性肝汁性肝硬化(又名原发性胆汁性胆合炎)诊断和治疗共识[J].临床肝胆病杂志.2015,31(12):1980-1988.

[12]DOHMEN K,WEN CY,NAGAOKA S,et al.Fenofibrate-induced liver injury[J].World J Gastroenterol,2005,11(48):7702-7703.

[13]TSIMIHODIMOS V,MILTIADOUS G,BAIRAKTARI E,et al.Possible mechanisms of the fibrate-induced increase in serum creatinine[J].Clin Nephrol,2002,57(5):407-408.

[14]IWASAKI S,TSUDA K,UETA H,et al.Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis[J].Hepatol Res,1999,16(1):12-18.

[15]HAN XF,WANG QX,LIU Y,et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis,2012,13(4):219-224.

[16]LENS S,LEOZ M,NAZAL L,et al.Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid[J].Liver Int,2014,34(2):197-203.

[17]HOSONUMA K,SATO K,YAMAZAKI Y,et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol,2015,110(3):423-431.

[18]CHEUNG AC,LAPOINTE-SHAW L,KOWGIER M,et al.Combined ursodeoxycholic acid(UDCA)and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Aliment Pharmacol Ther,2016,43(2):283-293.

[19]OHMOTO K,YOSHIOKA N,YAMAMOTO S.Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis[J].J Gastroenterol,2006,41(5):502-503.

[20]ZHANG Y,CHEN K,DAI W,et al.Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J].Hepatol Res,2015,45(1):48-58.

[21]ZHANG Y,LI S,HE L,et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis[J].Drug Des Devel Ther,2015,9:2757-2766.

[22]KUIPER EM,HANSEN BE,de VRIES RA,et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J].Gastroenterology,2009,136(4):1281-1287.

[23]HEGADE VS,KHANNA A,WALKER LJ,et al.Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score[J].Dig Dis Sci,2016,61(10):3037-3044.

[24]LEVY C,PETER JA,NELSON DR,et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther,2011,33(2):235-242.

[25]CUPERUS FJ,HALILBASIC E,TRAUNER M.Fibrate treatment for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2014,30(3):279-286.

[26]KLUTH M,STINDT J,DROGE C,et al.A mutation within the extended X loop abolished substrate-induced ATPase activity of the human liver ATP-binding cassette(ABC)transporter MDR3[J].J Biol Chem,2015,290(8):4896-4907.

[27]GHONEM NS,ANANTHANARAYANAN M,SOROKA CJ,et al.Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion[J].Hepatology,2014,59(3):1030-1042.

[28]NAKAMUTA M,FUJINO T,YADA R,et al.Therapeutic effect of bezafibrate against biliary damage:a study of phospholipid secretion via the PPARalpha-MDR3 pathway[J].Int J Clin Pharmacol Ther,2010,48(1):22-28.

[29]HONDA A,IKEGAMI T,NAKAMUTA M,et al.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J].Hepatology,2013,57(5):1931-1941.

[30]THOMAS M,BURK O,KLUMPP B,et al.Direct transcriptional regulation of human hepatic cytochrome P450 3A4(CYP3A4)by peroxisome proliferator-activated receptor alpha(PPARalpha)[J].Mol Pharmacol,2013,83(3):709-718.

[31]GHONEM NS,ASSIS DN,BOYER JL.Fibrates and cholestasis[J].Hepatology,2015,62(2):635-643.

[32]LI F,PATTERSON AD,KRAUSZ KW,et al.Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis[J].J Lipid Res,2012,53(8):1625-1635.

[33]MARX N,SUKHOVA GK,COLLINS T,et al.PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1expression in human endothelial cells[J].Circulation,1999,99(24):3125-3131.

[34]GALLI A,CRABB DW,CENI E,et al.Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro[J].Gastroenterology,2002,122(7):1924-1940.

[35]XIE C,LI L,XU YP,et al.Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis[J].Chin J Hepatol,2013,21(12):914-919.(in Chinese)谢聪,李龙,许雅苹,等.非诺贝特的抗小鼠肝纤维化作用[J].中华肝脏病杂志,2013,21(12):914-919.

施引文献

资源附件(0)

访问统计